DENALI THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.43 USD | +3.14% |
|
-3.56% | -28.10% |
| 04-09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
| 04-03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
Chart calendar Denali Therapeutics Inc.
e6033372986ebe3.7ok5BRnqkfOehrxgYGLKB_U0DGPqEbMDHQL0vIJXNH4.oOtOaVaf_IL3x9QnFhScVb9DXALZJ55OflPDzfcxUzSI62NxVaDDw-3W3w~46cc84f1814a03681fa0c9bd13332e74
Upcoming events on Denali Therapeutics Inc.
Past events on Denali Therapeutics Inc.
| 19/03/2024 19:00 | Stifel CNS Day |
| 11/03/2024 | Jefferies Biotech on the Bay Summit |
| 11/03/2024 14:00 | Leerink Partners Global Biopharma Conference |
| 05/03/2024 15:30 | TD Cowen Health Care Conference |
| 27/02/2024 13:05 | Q4 2023 Earnings Release |
| 08/02/2024 23:00 | WORLD Symposium - Poster No 34 |
| 08/02/2024 23:00 | WORLD Symposium - Poster No 80 |
| 08/02/2024 21:00 | WORLD Symposium |
| 08/02/2024 01:15 | WORLD Symposium |
| 07/02/2024 23:00 | WORLD Symposium - Poster No 43 |
| 07/02/2024 17:00 | WORLD Symposium |
| 07/02/2024 01:15 | WORLD Symposium |
| 09/01/2024 18:30 | JPMorgan Healthcare Conference |
| 16/11/2023 14:00 | Jefferies London Healthcare Conference |
| 08/11/2023 05:01 | Q3 2023 Earnings Release |
| 12/09/2023 16:30 | Morgan Stanley Global Healthcare Conference |
| 10/09/2023 | H.C. Wainwright Global Investment Conference |
| 28/08/2023 | Society for the Study of Inborn Errors of Metabolism Symposium |
| 08/08/2023 21:01 | Q2 2023 Earnings Release |
| 06/08/2023 | BTIG Virtual Biotechnology Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 26,7 28,4 -6.08% | 336 86,3 289.16% | 48,7 76,0 -35.96% | 108 110 -0.97% | 331 337 -2.06% | 65,8 |
|
EBITDA Million USD | Released Forecast Spread | -205 -188 -9.16% | 71,2 -96,0 174.26% | -287 -283 -1.4% | -330 -317 -4.15% | -180 -148 -21.82% | -417 |
|
EBIT Million USD | Released Forecast Spread | -213 -213 -0.24% | 62,7 -173 136.32% | -296 -267 -10.89% | -341 -339 -0.45% | -197 -181 -8.9% | -449 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -198 -196 -0.9% | 72,0 -232 131.07% | -291 -272 -6.97% | -326 -326 0.12% | -145 -134 -8.71% | -415 |
|
Net income Million USD | Released Forecast Spread | -198 -198 0.11% | 71,1 -233 130.51% | -291 -271 -7.08% | -326 -329 1.01% | -145 -136 -6.65% | -411 |
|
EPS USD | Released Forecast Spread | -2,07 -2,07 0.14% | 0,63 -2,17 129.02% | -2,39 -2,15 -11.08% | -2,60 -2,59 -0.47% | -1,06 -1,00 -5.93% | -2,62 |
| Announcement Date | 27/02/20 | 25/02/21 | 28/02/22 | 27/02/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 12,5 44,8 -72.08% | 42,1 33,3 26.46% | 52,5 44,7 17.52% | 3,56 17,0 -79.09% | 10,3 13,1 -21.6% | 35,1 29,9 17.62% | 294 39,5 644.49% | 1,27 11,2 -88.64% | 0,00 7,78 - | 13,0 | 12,8 | 12,6 | 12,3 |
|
EBITDA Million USD | Released Forecast Spread | -75,0 -55,0 -36.41% | -64,4 -56,1 -14.81% | -59,3 -33,3 -78.34% | -105 -86,7 -21.52% | -101 -71,1 -42.38% | -111 -71,8 -54.18% | 173 -81,0 313.4% | -130 -105 -24.4% | -111 | -101 | -108 | -90,6 | |
|
EBIT Million USD | Released Forecast Spread | -77,1 -48,1 -60.34% | -66,5 -63,7 -4.32% | -61,4 -67,0 8.35% | -107 -97,4 -10.33% | -105 -103 -1.79% | -121 -96,0 -25.87% | 170 -90,5 288.31% | -114 -117 3.14% | -133 -116 -14.35% | -118 | -111 | -113 | -110 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -75,8 -53,9 -40.65% | -65,2 -57,4 -13.7% | -58,8 -59,0 0.37% | -103 -93,8 -10.08% | -98,7 -94,2 -4.76% | -110 -91,6 -19.91% | 183 -117 257.21% | -99,4 -114 13.13% | -119 -108 -10.33% | -109 | -101 | -106 | -109 |
|
Net income Million USD | Released Forecast Spread | -75,3 -53,6 -40.43% | -65,2 -59,9 -8.95% | -58,8 -62,1 5.31% | -103 -93,9 -9.97% | -98,7 -99,4 0.76% | -110 -92,5 -18.66% | 183 -113 261.6% | -99,4 -112 11.35% | -119 -112 -6.88% | -106 | -101 | -103 | -107 |
|
EPS USD | Released Forecast Spread | -0,62 -0,46 -35.05% | -0,53 -0,50 -6.97% | -0,48 -0,52 7.63% | -0,84 -0,78 -7.16% | -0,75 -0,78 3.81% | -0,80 -0,70 -13.78% | 1,30 -0,86 251.9% | -0,72 -0,81 11.53% | -0,86 -0,81 -6.77% | -0,70 | -0,67 | -0,68 | -0,66 |
| Announcement Date | 28/02/22 | 05/05/22 | 08/08/22 | 03/11/22 | 27/02/23 | 08/05/23 | 08/08/23 | 07/11/23 | 27/02/24 | - | - | - | - |
More events
Past sector events for Denali Therapeutics Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- DNLI Stock
- Calendar Denali Therapeutics Inc.
